Experience to Support Your Cancer and Hematology Trials

PAREXEL’s extensive experience in conducting pivotal trials for oncology and hematology therapies helps you move your products through this critical stage of development quickly and efficiently so they can reach patients in need.  PAREXEL has managed hundreds of oncology trials involving nearly 175,000 patients over the last five years, so we know what it takes to successfully bring these new therapies through the critical Phase IIb/III process.  Those trials have encompassed many different classes of cancer therapeutics, including extensive work in cytotoxics,  biologics, targeted therapeutics, immunotherapies, vaccine therapies, and supportive-care products.  We also have one of the industry’s most extensive databases of investigators with oncology/hematology experience.

Equally important, PAREXEL’s depth of knowledge about cancer and blood disorders can help you overcome the difficulties of developing this therapies.  We have more than 30 trained oncologists and hematologists on staff – many of whom remain active in patient care and medical education.  In addition, PAREXEL has more than 350 CRAs and 50 project managers with direct oncology/hematology experience at locations around the world.  That gives us the resources and insight to help you meet the local regulatory requirements in whatever countries and cancer centers are the best fit for your trial program.

PAREXEL’s development partners also benefit from our industry-leading expertise in medical imaging technology, which is an increasingly important factor in demonstrating the efficacy and safety of oncology and hematology products.  We have assembled one of the finest medical imaging groups in the world , with radiologists and medical oncologists who can ensure that your image acquisition protocols meet the latest requirements from regulatory authorities, such as blinded evaluation by independent oncologists.